Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
33%(1 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

NCT05900895
completedphase_2

ER Reactivation Therapy for Breast Cancer

NCT02188745
completedphase_2

ELITE: Early Versus Late Intervention Trial With Estradiol

NCT00114517
completednot_applicable

Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)

NCT00668603

Clinical Trials (4)

Showing 4 of 4 trials
NCT05900895Phase 1

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Recruiting
NCT02188745Phase 2

ER Reactivation Therapy for Breast Cancer

Completed
NCT00114517Phase 2

ELITE: Early Versus Late Intervention Trial With Estradiol

Completed
NCT00668603Not Applicable

Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4